Patent application number | Description | Published |
20090098537 | Biomarker for Sensitivity to mTOR Inhibitor Therapy in Kidney Cancer - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells. | 04-16-2009 |
20090155787 | Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 06-18-2009 |
20100029676 | T315A AND F317I MUTATIONS OF BCR-ABL KINASE DOMAIN - The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins. | 02-04-2010 |
20100055687 | Mutations in the BCR-ABL tyrosine kinase associated with resistance to ST1-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 03-04-2010 |
20100248241 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 09-30-2010 |
20110045459 | Molecular determinants of EGFR kinase inhibitor response in glioblastoma - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregulated in pathologies such as cancer and to reagents and kits adapted for performing such methods. | 02-24-2011 |
20120021425 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 01-26-2012 |
20120282622 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 11-08-2012 |
Patent application number | Description | Published |
20080299589 | Methods and Materials for Examining the P13k/Akt Pathway in Gliomas and Prostate Cancers - The invention disclosed herein provides methods for the examination and/or quantification of the PI3K/Akt and Ras/MAPK biochemical pathways that are disregulated in pathologies such as cancers of the prostate and gliomas. The invention disclosed herein further provides reagents and kits adapted for performing such methods. | 12-04-2008 |
20090111864 | DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 04-30-2009 |
20090197893 | Methods of Identifying and Treating Individuals Exhibiting Complex Karyotypes - The invention described herein relates to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that harbor complex karyotypes. The present invention also related to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins. | 08-06-2009 |
20100172975 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 07-08-2010 |
20100210665 | DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 08-19-2010 |
20110003839 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES - A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders. | 01-06-2011 |
20120190718 | DIARYLTHIOHYDANTOIN COMPOUNDS - The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 07-26-2012 |
20120295944 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 11-22-2012 |
20130034501 | DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone lefiactory prostate cancer. | 02-07-2013 |
20130072511 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES - Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders. | 03-21-2013 |
20140309262 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES - Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders. | 10-16-2014 |
20140343111 | DIARYLTHIOHYDANTOIN COMPOUNDS - The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 11-20-2014 |
20150065546 | DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 03-05-2015 |